» Articles » PMID: 25283635

Suprabasin As a Novel Tumor Endothelial Cell Marker

Overview
Journal Cancer Sci
Specialty Oncology
Date 2014 Oct 7
PMID 25283635
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have reported that stromal cells contribute to tumor progression. We previously demonstrated that tumor endothelial cells (TEC) characteristics were different from those of normal endothelial cells (NEC). Furthermore, we performed gene profile analysis in TEC and NEC, revealing that suprabasin (SBSN) was upregulated in TEC compared with NEC. However, its role in TEC is still unknown. Here we showed that SBSN expression was higher in isolated human and mouse TEC than in NEC. SBSN knockdown inhibited the migration and tube formation ability of TEC. We also showed that the AKT pathway was a downstream factor of SBSN. These findings suggest that SBSN is involved in the angiogenic potential of TEC and may be a novel TEC marker.

Citing Articles

Aberrant tumor vasculature. Facts and pitfalls.

Ribatti D Front Pharmacol. 2024; 15:1384721.

PMID: 38576482 PMC: 10991687. DOI: 10.3389/fphar.2024.1384721.


KLK10 derived from tumor endothelial cells accelerates colon cancer cell proliferation and hematogenous liver metastasis formation.

Kato K, Noda T, Kobayashi S, Sasaki K, Iwagami Y, Yamada D Cancer Sci. 2024; 115(5):1520-1535.

PMID: 38475666 PMC: 11093189. DOI: 10.1111/cas.16144.


Improving the Efficacy of Common Cancer Treatments via Targeted Therapeutics towards the Tumour and Its Microenvironment.

Cecchi D, Jackson N, Beckham W, Chithrani D Pharmaceutics. 2024; 16(2).

PMID: 38399237 PMC: 10891984. DOI: 10.3390/pharmaceutics16020175.


Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point?.

Thomas J, Gireesh Moly A, Xavier H, Suboj P, Ladha A, Gupta G Front Oncol. 2023; 13:1063051.

PMID: 37056346 PMC: 10088512. DOI: 10.3389/fonc.2023.1063051.


Suprabasin enhances the invasion, migration, and angiogenic ability of oral squamous cell carcinoma cells under hypoxic conditions.

Houri A, Mukudai Y, Abe Y, Watanabe M, Nara M, Miyamoto S Oncol Rep. 2023; 49(5).

PMID: 36896786 PMC: 10035061. DOI: 10.3892/or.2023.8520.


References
1.
McDonald D, Baluk P . Significance of blood vessel leakiness in cancer. Cancer Res. 2002; 62(18):5381-5. View

2.
Hida K, Hida Y, Amin D, Flint A, Panigrahy D, Morton C . Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004; 64(22):8249-55. DOI: 10.1158/0008-5472.CAN-04-1567. View

3.
Glazer C, Smith I, Ochs M, Begum S, Westra W, Chang S . Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One. 2009; 4(12):e8189. PMC: 2781168. DOI: 10.1371/journal.pone.0008189. View

4.
Folkman J . Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2003; 29(6 Suppl 16):15-8. DOI: 10.1053/sonc.2002.37263. View

5.
Akiyama K, Ohga N, Maishi N, Hida Y, Kitayama K, Kawamoto T . The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma. Pathol Int. 2013; 63(1):37-44. DOI: 10.1111/pin.12031. View